PAUL Y. SONG
CHAIRMAN/CEO
NKGEN BIOTECH INC.
WHY: Developing a system of “natural killer” cells to battle cancer. Has built 25K-SF facility in Santa Ana and employs 57 companywide. Market cap usually around $30M.
IN THE NEWS: Shares soared 377% on March 6 as volume of 107M shares was 25X daily average. Volatility related to South Korean traders betting on a different investment by company founder.
NOTABLE: On May 20, company cleared by its Internal Review Board to start its Phase 2 clinical trial for its cell therapy called SNK01 to treat Alzheimer’s.
QUOTABLE: “The reality is we don’t have a lot of float — we are susceptible to these price swings. All we can control is continuing to meet our clinical goals.”
